Last reviewed · How we verify
omeprazole/sodium bicarbonate — Competitive Intelligence Brief
marketed
Proton pump inhibitor with antacid
H+/K+-ATPase (proton pump)
Gastroenterology
Small molecule
Live · refreshed every 30 min
Target snapshot
omeprazole/sodium bicarbonate (omeprazole/sodium bicarbonate) — Food and Drug Administration (FDA). Omeprazole inhibits gastric acid secretion by blocking the proton pump in stomach parietal cells, while sodium bicarbonate provides rapid acid neutralization.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| omeprazole/sodium bicarbonate TARGET | omeprazole/sodium bicarbonate | Food and Drug Administration (FDA) | marketed | Proton pump inhibitor with antacid | H+/K+-ATPase (proton pump) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Proton pump inhibitor with antacid class)
- Food and Drug Administration (FDA) · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- omeprazole/sodium bicarbonate CI watch — RSS
- omeprazole/sodium bicarbonate CI watch — Atom
- omeprazole/sodium bicarbonate CI watch — JSON
- omeprazole/sodium bicarbonate alone — RSS
- Whole Proton pump inhibitor with antacid class — RSS
Cite this brief
Drug Landscape (2026). omeprazole/sodium bicarbonate — Competitive Intelligence Brief. https://druglandscape.com/ci/omeprazole-sodium-bicarbonate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab